stick with obviously the Pharma sector and talk about what we're seeing in Nova vax today because we're seeing a huge move following their earnings report you're looking at shares really moving to the downside the company slashing its revenue forecast actually now we're looking at Gaines of just about 2% so a bit of a reversal there I'm curious and this is a stock that tends to be extremely volatile following the earnings reports that we are getting but I'm curious there's a lot riding obviously just in terms of what demand is going to look like for the vaccine whether or not they're going to see that updated shot here for the fall season and and what is ultimately going to look like on a global scale as well what do you see the future looking like here for novaa amidst all of that uncertainty yeah it for sure this is a super volatile stock um not that surprised that it's up today when you just look at the valuation of a company that's worth a little bit more than a billion and is still going to do roughly 400 to 500 million in sales next year with the vaccine you're not looking at a at a huge multiple um but when you look at when you kind of like zoom out here this covid market for vaccines I think is going to be incredibly disappointing not only this year but in the out years barring some unforeseen pickup in a very severe strain um of the virus which has not really happened in some time now we're four years away from Peak pandemic levels we've really not seen anything overly um discouraging or concerning um relating to the virus in a number of years I just think the population is kind of vaccin out I've been saying that for a while I do think there's an you know there's a faction of the population that you know wants this Extra Protection every year um the elderly people with you know a lot of comorbidities that are very very kind of paranoid about what getting Co again could do but I feel like we're in the midst of just a market in perpetual ual decline so for novax that has a low Revenue base it's a little bit different um because again it's a one $1.2 billion company you can kind of make the numbers work but you know broadly speaking I just feel like covid vaccines as we know them are going to decline for a number of years